YonaLink, a pioneering company in virtual healthcare, is poised to replace that. In an in-depth interview with editor-in-chief Liza Laws, Yonalink co-founder Gav Martell shared his journey, the company’s innovative technology, and promising long-term clinical trials.
Gav Martell’s adventure at Yonalink is a testament to the strength of interdisciplinary collaboration and a willingness to solve real-world disorders. With a background in software and hardware, Martell has been at the intersection of complex and regulated industries. “I started my career at IBM and have worked in highly regulated industries,” Martell explained. “I’ve worked at a broadcasting company working with the FCC, a drone company with the FAA, and now in the healthcare industry with the FDA. “The goal is to simplify complex disorders to make things less difficult for other people. “
The concept for the company was born out of Martell’s interactions with Iddo Peleg, a healthcare veteran who is CEO and co-founder. “Iddo kept telling me about this challenge in virtual healthcare, where clinical trials involve manually copying data from hospital records to capture it. systems,” recalls Martell. For several months, he convinced me that this was the next big challenge we had to face, and that’s why we introduced Yonalink in 2019. “
The YonaLink EDC, on the other hand, is a classic knowledge capture formula enhanced through trendy technology. “The magic happens when you mix the two,” Martell said. “Hospital knowledge is placed precisely in the right fields in the EDC formula, which saves time. and prices and quality of knowledge. “
Ensuring the accuracy and integrity of knowledge is paramount in clinical trials. Martell noted that the company’s formula complies with all mandatory regulations, adding HIPAA and GDPR. “In our pilot, we achieved one hundred percent accuracy of the knowledge transferred,” he said. “The procedure includes a built-in audit where knowledge is reviewed before it is fully incorporated into the formula. “
This meticulous technique ensures that any anomalies or errors are quickly detected. “The most productive practices of the software and our AI engine play a role in maintaining this peak of accuracy,” Martell added.
The progression of this generation has not been without its challenges. Initially, the team envisioned their platform as an undeniable pipeline between hospitals and existing EDC formulas. “We thought we’d just be a pipe in the middle,” Martell explained. “But I learned that none of the EDCs knew what to do with knowledge transmission. So, in 2020, we started from scratch and created a formula that could manage knowledge transmission with AI to position knowledge accurately.
This twist was about making the formula physically powerful and adaptable. “Our formula now supports the transmission of knowledge from a variety of sources, adding medical devices and patient questionnaires,” Martell said.
At the heart of his project is the democratization of clinical trials. “Today, most clinical trials are conducted at a small number of sites, making them expensive and logistically difficult,” Martell explained. “Our goal is to lower the bar for participation in medical sites, thereby expanding patient and trial diversity. “
By reducing the workload and prices of medical sites, YonaLink aims to make clinical trials more viable and widespread. “This means that more patients can conduct trials, especially those in remote or underserved areas,” Martell added.
YonaLink has garnered incredibly positive feedback from medical centers and sponsors. “People love our product and our company,” Martell explained. “A new consumer recently told me that the referrals he gained were the most enthusiastic he had ever met. That’s because we’re solving a real-world challenge that has a significant impact on day-to-day operations.
The impact on clinical trial staffing has been profound. “Study coordinators and site staff tell us that manually copying data is the most tedious part of their job,” Martell said. “With Yonalink, we automate a lot of this task, making your paintings more satisfying and less error-prone. “
Data privacy and security are very important considerations in the healthcare industry. Yonalink solves these disorders with strict measures. ” All our systems are GDPR compliant and we perform audits and penetration tests,” Martell said. “We also ensure that knowledge is locally controlled to comply with regional regulations. “
Looking ahead, Yonalink aims to expand its network of connected hospitals and its knowledge transfer capabilities. “We are racing to close the hole in the dissemination of unstructured knowledge, such as medical notes and AI-scanned images,” Martell revealed. By the end of the year, we hope to publish even more types of knowledge to make our formula even more complete. “
AI and automation are poised to revolutionize the clinical trial landscape. Martell, with its extensive experience in the field of software, sees the prospects and challenges. “AI can especially speed up processes and improve accuracy,” he said. “However, he will have to be followed with caution, because he is not perfect. “
Martell shared a personal anecdote about experimenting with AI in his kitchen, highlighting its versatility and potential. “I use ChatGPT as a sous chef to help me with culinary tasks, showing how AI can have compatibility with different facets of life,” he said. .
The company has created strategic partnerships to further its mission. “We have a partnership with Sheba Medical Center in Israel and collaborate with companies like ProofPilot,” Martell said. “We are also in discussions with several lead CROs, which we hope to announce soon. “.
Yonalink’s innovative strategy for clinical trials is poised to transform the industry. By automating the flow of data and ensuring accuracy, the company not only improves efficiency, but also improves the overall quality of clinical trials. With a transparent vision and a strong technological foundation, Gav Martell and his team are paving the way for more clinical trials to become available and effective, with the ultimate goal of making a significant impact on global healthcare.
As YonaLink continues to grow and evolve, its commitment to solving real global disruptions and patient access to clinical trials remains unwavering. “We’re not just a technology company; we are here to replace the world of clinical trials,” Martell concluded.
More Promotional Features